How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Home Sexually Transmitted Diseases Test Kit Market
- By Test Type: Chlamydia Test Kit, Gonorrhea Test Kit, HIV Test Kit, Syphilis Test Kit, Herpes Simplex Virus (HSV) Test Kit, Trichomoniasis Test Kit
- By Sample Type: Urine Sample Test Kit, Blood Sample Test Kit, Swab Sample Test Kit, Saliva Sample Test Kit
- By Distribution Channel: Online Pharmacy, Retail Pharmacy, Direct-to-Consumer Websites, Healthcare Providers
- By End User: Individual Consumers, Healthcare Professionals, Sexual Health Clinics
- By Technology: Nucleic Acid Amplification Test (NAAT), Immunoassay Test, Rapid Antigen Test, Enzyme-Linked Immunosorbent Assay (ELISA)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Chlamydia Test Kit leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 11 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 11 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Home Sexually Transmitted Diseases Test Kit Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 11 company profiles, forecast to 2033.
Segmentation covered
Test Type 6
Sample Type 4
Distribution Channel 4
End User 3
Technology 4
Companies profiled
Everlywell Inc.
LetsGetChecked Ltd.
myLAB Box
Nurx
STDcheck.com
Verisana GmbH
Maven Clinic
Pill Club
BioIQ
Pixel by LabCorp
Quest Diagnostics
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
11 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Everlywell Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →LetsGetChecked Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →myLAB Box
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nurx
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →STDcheck.com
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Verisana GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Maven Clinic
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Pill Club
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →BioIQ
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Pixel by LabCorp
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Quest Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,042M by 2033 · 6.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Chlamydia Test Kit46.6
- Gonorrhea Test Kit14.4
- HIV Test Kit8.3
- Syphilis Test Kit8.2
- Herpes Simplex Virus (HSV) Test Kit14.7
- Trichomoniasis Test Kit7.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,604M → $2,629M · 6.4%
Europe$1,118M → $1,863M · 6.6%
Asia Pacific$1,021M → $1,813M · 7.4%
Latin America$631.8M → $943.0M · 5.1%
Middle East and Africa$486.0M → $886.9M · 7.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.462026
6.452027
6.482028
6.482029
6.492030
6.512031
6.532032
6.542033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Everlywell Inc.15.8
- LetsGetChecked Ltd.22.0
- myLAB Box12.1
- Nurx7.7
- STDcheck.com5.2
- Verisana GmbH9.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type18.8%
Sample Type23.2%
Distribution Channel31.0%
End User12.8%
Technology14.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe22.9
- Asia Pacific22.3
- Latin America11.6
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Everlywell Inc. | 77 | 79 | 85 | 87 | 79 | 84 | 82 |
| LetsGetChecked Ltd. | 85 | 88 | 71 | 83 | 82 | 91 | 83 |
| myLAB Box | 86 | 70 | 74 | 81 | 87 | 67 | 78 |
| Nurx | 63 | 63 | 71 | 74 | 58 | 65 | 66 |
| STDcheck.com | 60 | 70 | 73 | 61 | 60 | 68 | 65 |
| Verisana GmbH | 65 | 48 | 62 | 47 | 51 | 54 | 55 |
| Maven Clinic | 46 | 49 | 41 | 62 | 63 | 54 | 53 |
| Pill Club | 39 | 47 | 56 | 44 | 46 | 52 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Everlywell Inc.
- LetsGetChecked Ltd.
- myLAB Box
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Everlywell Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| LetsGetChecked Ltd. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| myLAB Box | ✓ | − | ✓ | ◐ | ✓ | ✓ |
| Nurx | − | − | ◐ | ✓ | ◐ | ◐ |
| STDcheck.com | ◐ | − | ◐ | − | − | ◐ |
| Verisana GmbH | ◐ | − | ◐ | − | ◐ | − |
| Maven Clinic | − | − | − | ◐ | − | ◐ |
| Pill Club | − | ◐ | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1LetsGetChecked Ltd.83
2Everlywell Inc.82
3myLAB Box78
4Nurx66
5STDcheck.com65
6Verisana GmbH55
7Maven Clinic53
8Pill Club47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Everlywell Inc.LetsGetChecked Ltd.myLAB Box
Contender2
Focused players with pockets of strength.
NurxSTDcheck.com
Niche3
Specialists in a single segment or region.
Verisana GmbHMaven ClinicPill Club
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Home Sexually Transmitted Diseases Test Kit Market — a $325M beachhead inside a $4.68B market.
Beachhead (SOM)$325Mobtainable near-term
Serviceable (SAM)$1.78Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Chlamydia Test Kit
Best fit — highest urgency & budget in Test Type.
Economic buyer77 fit
Gonorrhea Test Kit
Strong fit — clear ROI and a fast path to value.
End user69 fit
HIV Test Kit
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sample Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Home Sexually Transmitted Diseases Test Kit Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified24%
Evaluation12%
Closed-won7%
$9.7KCAC
$54KLTV
5.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Home Sexually Transmitted Diseases Test Kit Market is a high-growth opportunity — $12.9B by 2033, compounding at 11.0%.
TAM · 2025$5.59Btoday
TAM · 2033$12.9Bforecast
CAGR11.0%2027–2033
Cumulative$79.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$12.9BTotal addressable market
SAM$5.39BServiceable available market
SOM$956MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.0% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
11+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$12.9BLarge & growingTAM by 2033 at 11.0% CAGR
$5.39BServiceable nowreachable with today’s model
$956MBeachhead winobtainable near-term share
11+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$10.1BBear7.2% CAGR
$12.9BBase11.0% CAGR
$16.5BBull14.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sample Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Home Sexually Transmitted Diseases Test Kit Market — a $5.17B market by 2033. Plan: grow share from 7.4% to 16.4%.
Market size · 2033$5.17Btotal addressable
Market CAGR8.5%2027–2033
Target share16.4%from 7.4% today
Revenue ambition$848Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.4% | 16.4% | Ahead |
| Revenue | $390M | $848M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 35.6% | 40.3% | At risk |
| Customer retention | 85.9% | 93.2% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Sample Type capability
A defensible second engine — invest in Sample Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sample Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $120M capacity & capability investment
- Greenlight bolt-on M&A in Sample Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Home Sexually Transmitted Diseases Test Kit Market conversation — a $10.4B market you can size, segment and defend in minutes.
Market size · 2033$10.4Btotal opportunity
Growth8.3%CAGR to 2033
Addressable buyers1,063+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 3 mopayback period
$53K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
11+players profiled in this market
Coverage includes
Everlywell Inc.LetsGetChecked Ltd.myLAB BoxNurxSTDcheck.comVerisana GmbHMaven ClinicPill Club+3 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Home Sexually Transmitted Diseases Test Kit Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Home Sexually Transmitted Diseases Test Kit Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Home Sequential Compression Devices Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportHome Respiratory Therapy Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportHome Respiratory Therapy Equipment Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportHome Respiratory Support Equipment Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportHome Respiratory Monitor Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportHome Rehabilitation Medical Equipment and Services Market
Market size, share, segmentation and regional forecast.
$464M market · 2025 base year
View reportHome Rehabilitation Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportHome Rehabilitation Equipment Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportHome Pulse Oximeter Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportHome PSA Oxygen Generator Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportHome Portable Peak Flow Meter Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportHome Portable Oxygen Concentrator Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.